🔎 Trials Near Me

Beranda › Glioma Pontin Intrinsik Difus › Colorado

Uji klinis Glioma Pontin Intrinsik Difus di Colorado

8 studi untuk Glioma Pontin Intrinsik Difus mencari peserta di lokasi di Colorado.

Kota di Colorado

Teks studi resmi (Bahasa Inggris)

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

  • Children's Hospital Colorado, Aurora
Menerima pesertaFase 2
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06838676

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Children's Hospital Colorado, Aurora
Menerima pesertaFase 1/2
12 Months – 21 Years · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT04870944

Targeted Pediatric High-Grade Glioma Therapy

  • Children's Hospital Colorado, Aurora
Menerima pesertaStudi observasional
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05839379

Study of Olutasidenib and Temozolomide in HGG

  • Children's Hospital Colorado, Aurora
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06161974

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  • Children's Hospital Colorado, Aurora
Menerima pesertaFase 2
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05096481

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Children's Hospital Colorado, Aurora
Menerima pesertaFase awal 1Sukarelawan sehat diterima
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Children's Hospital Colorado, Aurora
Menerima pesertaFase 2
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 29 Mei 2026 · NCT05843253

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

  • Children's Hospital Colorado, Aurora
Menerima pesertaFase awal 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 18 Mar 2026 · NCT04655404

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.